Free Trial

Ultragenyx Pharmaceutical (RARE) Short Interest Ratio & Short Volume

Ultragenyx Pharmaceutical logo
$40.00 -0.85 (-2.08%)
As of 01/17/2025 04:00 PM Eastern

Ultragenyx Pharmaceutical Short Interest Data

Ultragenyx Pharmaceutical (RARE) has a short interest of 4.02 million shares. This marks a 8.36% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.0, indicating that it would take 5.0 days of the average trading volume of 862,608 shares to cover all short positions.

Current Short Interest
4,020,000 shares
Previous Short Interest
3,710,000 shares
Change Vs. Previous Month
+8.36%
Dollar Volume Sold Short
$169.12 million
Short Interest Ratio
5.0 Days to Cover
Last Record Date
December 31, 2024
Outstanding Shares
92,340,000 shares
Percentage of Shares Shorted
4.35%
Today's Trading Volume
794,388 shares
Average Trading Volume
862,608 shares
Today's Volume Vs. Average
92%
Short Selling Ultragenyx Pharmaceutical?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

RARE Short Interest Over Time

RARE Days to Cover Over Time

RARE Percentage of Float Shorted Over Time

Ultragenyx Pharmaceutical Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
12/31/20244,020,000 shares $169.12 million +8.4%N/A5 $42.07
12/15/20243,710,000 shares $169.84 million +9.8%N/A5 $45.78
11/30/20243,380,000 shares $160.99 million +0.9%N/A4.8 $47.63
11/15/20243,350,000 shares $149.91 million +5.4%N/A4.7 $44.75
10/31/20243,180,000 shares $162.15 million +0.6%N/A4.5 $50.99
10/15/20243,160,000 shares $180.50 million +9.3%N/A4.7 $57.12
9/30/20242,890,000 shares $160.54 million -19.9%N/A4.1 $55.55
9/15/20243,610,000 shares $212.05 million +2.9%N/A4.7 $58.74
8/31/20243,510,000 shares $199.30 million -8.8%N/A4.1 $56.78
8/15/20243,850,000 shares $199.16 million -9.0%N/A4.3 $51.73
7/31/20244,230,000 shares $190.43 million -3.0%N/A4.8 $45.02
7/15/20244,360,000 shares $193.85 million +2.8%N/A5.1 $44.46
6/30/20244,240,000 shares $174.26 million -15.9%N/A4.8 $41.10
6/15/20245,040,000 shares $196.81 million +12.8%N/A6.2 $39.05
5/31/20244,470,000 shares $179.43 million +3.0%N/A6.1 $40.14
5/15/20244,340,000 shares $178.46 million -6.7%N/A5.9 $41.12
4/30/20244,650,000 shares $197.81 million +6.2%N/A6.3 $42.54
4/15/20244,380,000 shares $187.77 million +11.7%N/A6.3 $42.87
3/31/20243,920,000 shares $183.02 million +3.7%N/A5.3 $46.69
3/15/20243,780,000 shares $179.06 million -2.3%N/A5 $47.37
2/29/20243,870,000 shares $200.16 million +8.7%N/A4.9 $51.72
2/15/20243,560,000 shares $164.69 million +4.4%N/A4.6 $46.26
1/31/20243,410,000 shares $150.42 million -17.2%N/A4.3 $44.11
1/15/20244,120,000 shares $188.28 million +1.5%N/A4.4 $45.70
12/31/20234,060,000 shares $194.15 million +21.6%N/A4.1 $47.82
12/15/20233,340,000 shares $153.54 million +3.1%N/A3.4 $45.97
11/30/20233,240,000 shares $125.87 million -7.4%N/A3.4 $38.85
11/15/20233,500,000 shares $136.78 million -15.9%N/A3.8 $39.08
10/31/20234,160,000 shares $147.26 million +24.6%N/A4.6 $35.40
10/15/20233,340,000 shares $112.12 million -15.0%5.0%4 $33.57
9/30/20233,930,000 shares $140.10 million +15.6%5.9%6.3 $35.65
9/15/20233,400,000 shares $128.11 million -1.5%5.1%6 $37.68
8/31/20233,450,000 shares $126.93 million -1.7%5.2%6.2 $36.79
8/15/20233,510,000 shares $134.75 million -1.1%5.3%6.2 $38.39
7/31/20233,550,000 shares $153.08 million -10.4%5.4%5.9 $43.12
7/15/20233,960,000 shares $174.95 million +6.5%6.0%6.4 $44.18
6/30/20233,720,000 shares $171.60 million +22.0%5.7%5.7 $46.13
6/15/20233,050,000 shares $149.02 million -4.1%4.7%4.5 $48.86
5/31/20233,180,000 shares $156.96 million -8.9%4.9%4.8 $49.36
5/15/20233,490,000 shares $171.08 million +17.1%5.3%5.5 $49.02
4/30/20232,980,000 shares $130.14 million +4.2%4.6%4.9 $43.67
4/15/20232,860,000 shares $109.25 million -8.0%4.4%4.8 $38.20
3/31/20233,110,000 shares $124.71 million +4.4%4.8%5.2 $40.10
3/15/20232,980,000 shares $121.38 million -3.3%4.6%5 $40.73
2/28/20233,080,000 shares $137.03 million -6.4%4.7%4.8 $44.49
2/15/20233,290,000 shares $145.45 million -3.2%5.1%4.8 $44.21
1/31/20233,400,000 shares $154.12 million -4.8%5.2%4.6 $45.33
1/15/20233,570,000 shares $155.47 million +6.3%5.5%4.7 $43.55
12/30/20223,360,000 shares $155.67 million -1.2%5.2%4.3 $46.33
12/15/20223,400,000 shares $154.94 million +14.1%5.2%4.2 $45.57
11/30/20222,980,000 shares $108.17 million -1.3%4.6%3.8 $36.30
11/15/20223,020,000 shares $107.09 million +2.0%4.7%4.1 $35.46
10/31/20222,960,000 shares $119.76 million -8.6%4.6%4.1 $40.46
10/15/20223,240,000 shares $120.07 million +5.9%5.0%4.5 $37.06
9/30/20223,060,000 shares $126.71 million -1.9%4.7%4.1 $41.41
9/15/20223,120,000 shares $147.51 million +6.5%4.8%4.5 $47.28
8/31/20222,930,000 shares $139.73 million -3.9%4.5%4.2 $47.69
8/15/20223,050,000 shares $156.16 million +7.4%4.7%4.4 $51.20
7/31/20222,840,000 shares $151.32 million -5.0%4.4%4.1 $53.28
7/15/20222,990,000 shares $193.60 million +3.5%4.6%4.6 $64.75
6/30/20222,890,000 shares $172.42 million +7.0%4.5%5.1 $59.66
6/15/20222,700,000 shares $136.92 million +0.4%4.2%4.9 $50.71
5/31/20222,690,000 shares $126.16 million -10.9%4.2%5.2 $46.90
5/15/20223,020,000 shares $155.44 million -1.3%4.7%6.2 $51.47
4/30/20223,060,000 shares $216.31 million +5.9%4.8%6.9 $70.69
4/15/20222,890,000 shares $246.81 million +2.5%4.5%6.7 $85.40
3/31/20222,820,000 shares $204.79 million -3.8%4.4%6.6 $72.62
3/15/20222,930,000 shares $186.61 million -3.3%4.6%7.1 $63.69
2/28/20223,030,000 shares $203.98 million -8.5%4.7%7.3 $67.32
2/15/20223,310,000 shares $243.45 million -4.9%5.2%7.6 $73.55
1/31/20223,480,000 shares $243.36 million -0.3%5.5%8.5 $69.93
1/15/20223,490,000 shares $251.45 million +0.6%5.5%8.5 $72.05
12/31/20213,470,000 shares $291.79 million -11.5%5.5%8.2 $84.09
12/15/20213,920,000 shares $325.56 million -1.3%6.2%9.2 $83.05
11/30/20213,970,000 shares $298.66 million -2.7%6.3%9.5 $75.23
11/15/20214,080,000 shares $328.60 million +10.3%6.5%10.6 $80.54
10/29/20213,700,000 shares $310.50 million -3.9%5.9%9.1 $83.92
10/15/20213,850,000 shares $308 million -4.0%6.1%9.3 $80.00
9/30/20214,010,000 shares $361.66 million +3.9%6.4%9.7 $90.19
9/15/20213,860,000 shares $374.42 million -4.0%6.1%7 $97.00
8/31/20214,020,000 shares $387.09 million -0.7%6.4%6.7 $96.29
8/13/20214,050,000 shares $375.60 million -0.5%6.4%6.6 $92.74
7/30/20214,070,000 shares $324.91 million +3.0%6.5%6.6 $79.83
7/15/20213,950,000 shares $334.76 million +4.5%6.3%6.5 $84.75
6/30/20213,780,000 shares $360.42 million -23.6%6.0%6.3 $95.35
6/15/20214,950,000 shares $495.20 million -2.6%7.8%10.4 $100.04
5/28/20215,080,000 shares $516.69 million -1.0%8.0%11.6 $101.71
5/14/20215,130,000 shares $547.42 million -6.0%N/A12.1 $106.71
4/30/20215,460,000 shares $619.76 million +1.1%N/A12.4 $113.51
4/15/20215,400,000 shares $583.04 million -2.0%N/A13.1 $107.97
3/31/20215,510,000 shares $617.45 million -0.5%N/A12.1 $112.06
3/15/20215,540,000 shares $703.30 million -5.5%N/A11.2 $126.95
2/26/20215,860,000 shares $798.43 million +10.4%N/A11.6 $136.25
2/12/20215,310,000 shares $864.36 million -0.4%N/A10.9 $162.78
1/29/20215,330,000 shares $749.40 million -3.3%N/A11.3 $140.60
1/15/20215,510,000 shares $770.68 million -5.3%N/A10.1 $139.87
12/31/20205,820,000 shares $840.23 million -7.6%N/A11.3 $144.37
12/15/20206,300,000 shares $965.29 million -4.1%N/A14.2 $153.22
11/30/20206,570,000 shares $804.30 million -4.0%N/A15.4 $122.42
11/15/20206,840,000 shares $801.78 million -3.3%N/A16.4 $117.22
10/30/20207,070,000 shares $671.65 million -4.3%N/A17.4 $95.00
10/15/20207,390,000 shares $684.98 million +5.4%13.2%22.3 $92.69
9/30/20207,010,000 shares $576.15 million +1.7%12.5%20.3 $82.19
9/15/20206,890,000 shares $559.67 million +1.6%12.3%16.9 $81.23
8/31/20206,780,000 shares $576.71 million -0.9%12.1%15.7 $85.06
8/14/20206,840,000 shares $582.15 million -14.7%12.2%15.2 $85.11
7/31/20208,020,000 shares $626.84 million No Change14.3%16.1 $78.16
7/15/20208,020,000 shares $684.99 million +4.6%14.5%15.2 $85.41
6/30/20207,670,000 shares $564.97 million +3.4%13.7%13.7 $73.66
6/15/20207,420,000 shares $513.54 million -2.2%13.3%13.5 $69.21
5/29/20207,590,000 shares $520.60 million +0.8%13.6%13 $68.59
5/15/20207,530,000 shares $536.81 million +1.4%13.5%12.7 $71.29
4/30/20207,430,000 shares $448.99 million No Change13.3%13.1 $60.43
4/15/20207,430,000 shares $416.90 million -1.1%13.5%13.7 $56.11
3/31/20207,510,000 shares $497.39 million +8.1%13.6%12.5 $66.23
3/13/20206,949,400 shares $364.84 million +6.9%12.8%14.5 $52.50
2/28/20206,500,000 shares $247.85 million +1.4%12.0%12.7 $38.13
2/14/20206,410,000 shares $315.24 million -4.2%11.8%11.9 $49.18
1/31/20206,690,000 shares $372.70 million +4.0%12.5%12.2 $55.71

RARE Short Interest - Frequently Asked Questions

What is Ultragenyx Pharmaceutical's current short interest?

Short interest is the volume of Ultragenyx Pharmaceutical shares that have been sold short but have not yet been covered or closed out. As of December 31st, investors have sold 4,020,000 shares of RARE short. Learn More on Ultragenyx Pharmaceutical's current short interest.

What is a good short interest ratio for Ultragenyx Pharmaceutical?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RARE shares currently have a short interest ratio of 5.0. Learn More on Ultragenyx Pharmaceutical's short interest ratio.

Which institutional investors are shorting Ultragenyx Pharmaceutical?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ultragenyx Pharmaceutical: Jane Street Group LLC, and Walleye Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Ultragenyx Pharmaceutical's short interest increasing or decreasing?

Ultragenyx Pharmaceutical saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 4,020,000 shares, an increase of 8.4% from the previous total of 3,710,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Ultragenyx Pharmaceutical's short interest compare to its competitors?

Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Ultragenyx Pharmaceutical: Genmab A/S (0.22%), Viatris Inc. (2.96%), Intra-Cellular Therapies, Inc. (1.87%), Summit Therapeutics Inc. (2.70%), Moderna, Inc. (11.03%), Dr. Reddy's Laboratories Limited (1.57%), Sarepta Therapeutics, Inc. (5.37%), Catalent, Inc. (8.12%), Qiagen (1.38%), Vaxcyte, Inc. (11.49%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.83 billion), Charter Communications, Inc. ($3.77 billion), Reddit, Inc. ($2.98 billion), The Kroger Co. ($2.97 billion), International Paper ($2.64 billion), SoFi Technologies, Inc. ($1.99 billion), Rivian Automotive, Inc. ($1.93 billion), Onsemi ($1.81 billion), SoundHound AI, Inc. ($1.59 billion), and Moderna, Inc. ($1.57 billion). View all of the most shorted stocks.

What does it mean to sell short Ultragenyx Pharmaceutical stock?

Short selling RARE is an investing strategy that aims to generate trading profit from Ultragenyx Pharmaceutical as its price is falling. RARE shares are trading down $0.85 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Ultragenyx Pharmaceutical?

A short squeeze for Ultragenyx Pharmaceutical occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of RARE, which in turn drives the price of the stock up even further.

How often is Ultragenyx Pharmaceutical's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RARE, twice per month. The most recent reporting period available is December, 31 2024.




This page (NASDAQ:RARE) was last updated on 1/18/2025 by MarketBeat.com Staff
From Our Partners